← Leaderboards
James B McLachlan
University Of Minnesota
$6,028,986
Attributed
$7,695,301
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,695,301 · 5
By mechanism
R01$4,815,056 · 2
U01$2,385,241 · 1
R21$413,875 · 1
F32$81,129 · 1
Top collaborators
- Lisa A Morici4 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Erik T Yukl$2,308,453
- David Masopust$22,435,964
- Stephen C Jameson$24,805,124
- Mark R. Schleiss$10,248,102
- Bruce R. Blazar$144,460,093
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseCd4 Positive T LymphocytesAntigensT-LymphocyteImmune ResponsePhenotypeImmunityMissionCellsInfectionHuman DiseaseAffectPlayImmunePathogenInsightLymphoid TissueAntigen PresentationTissuesMhc Class Ii GenesInvestigationB-LymphocytesLymph NodesAntibody Formation
Grant awards (17)
Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity$1,326,308
R01 · FY2025 · AI · contact PI
Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity$660,395
R01 · FY2024 · AI · contact PI
Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity$660,395
R01 · FY2023 · AI · contact PI
Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity$685,533
R01 · FY2022 · AI · contact PI
Using combination adjuvants to direct and control immune responses at the intestinal mucosa$380,675
U01 · FY2020 · AI · contact PI
Using combination adjuvants to direct and control immune responses at the intestinal mucosa$380,675
U01 · FY2019 · AI · contact PI
Using combination adjuvants to direct and control immune responses at the intestinal mucosa$683,976
U01 · FY2018 · AI · contact PI
Using combination adjuvants to direct and control immune responses at the intestinal mucosa$546,615
U01 · FY2017 · AI · contact PI
Mast cell control of endogenous, antigen-specific CD4 T cell immunity$188,125
R21 · FY2017 · AI · contact PI
Using combination adjuvants to direct and control immune responses at the intestinal mucosa$393,300
U01 · FY2016 · AI · contact PI
Organ-specific CD4 T cell responses regulate Salmonella persistence$376,250
R01 · FY2016 · AI · contact PI
Mast cell control of endogenous, antigen-specific CD4 T cell immunity$225,750
R21 · FY2016 · AI · contact PI
Organ-specific CD4 T cell responses regulate Salmonella persistence$376,250
R01 · FY2015 · AI · contact PI
Organ-specific CD4 T cell responses regulate Salmonella persistence$376,250
R01 · FY2014 · AI · contact PI
Organ-specific CD4 T cell responses regulate Salmonella persistence$353,675
R01 · FY2013 · AI · contact PI
Antigen presentation to T cells in nonlymphoid tissue$32,333
F32 · FY2007 · AI · contact PI
Antigen presentation to T cells in nonlymphoid tissue$48,796
F32 · FY2006 · AI · contact PI